Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
December 13, 2021 16:15 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to...
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
November 15, 2021 07:00 ET
|
Centessa Pharmaceuticals plc
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate...
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
November 10, 2021 16:45 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the...
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
November 01, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ...
Orexia Therapeutics, empresa filial de Centessa Pharmaceuticals, y Schrödinger anuncian una colaboración para descubrir nuevos agonistas de los receptores de orexina
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ El trabajo de investigación se centrará en moléculas pequeñas con perfiles clínicos diferenciados para aprovechar el gran potencial del agonismo de la orexina en distintas indicaciones ~ ~ Es la...
Дочерняя компания Centessa Pharmaceuticals, Orexia Therapeutics и Schrödinger объявляют о сотрудничестве для открытия новых агонистов рецепторов орексина
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Исследования будут сосредоточены на малых молекулах с дифференцированными клиническими профилями, чтобы использовать широкий потенциал агонизма орексина по разным показаниям ~ ~ Впервые Schrödinger...
La consociata di Centessa Pharmaceuticals, Orexia Therapeutics, e Schrödinger annunciano una collaborazione per studiare nuovi agonisti del recettore dell'oressina
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ La ricerca si concentrerà su piccole molecole con profili clinici differenziati per sfruttare l'ampio potenziale dell'agonismo dell'oressina per diverse indicazioni terapeutiche ~ ~ Per la prima...
Centessa Pharmaceuticals, Tochtergesellschaft Orexia Therapeutics und Schrödinger kündigen Zusammenarbeit bei der Entdeckung neuartiger Orexin-Rezeptor-Agonisten an
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Der Schwerpunkt der Entdeckungsbemühungen wird auf kleinen Molekülen mit differenzierten klinischen Profilen liegen, mit dem Ziel, das große Potenzial des Orexin-Agonismus bei verschiedenen...
Orexia Therapeutics, filiale de Centessa Pharmaceuticals, et Schrödinger annoncent une collaboration visant à découvrir de nouveaux agonistes des récepteurs de l'orexine
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ Les efforts de découverte se concentreront sur de petites molécules avec des profils cliniques différenciés dans le but d'exploiter le vaste potentiel de l'agonisme de l'orexine à travers...
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics en Schrödinger kondigen samenwerking aan om nieuwe orexine-receptoragonisten te ontdekken
October 20, 2021 12:01 ET
|
Centessa Pharmaceuticals plc
~ De ontdekkingsinspanningen richten zich op kleine moleculen met gedifferentieerde klinische profielen om het brede potentieel van orexine-agonisme te benutten bij verschillende indicaties ~ ~ De...